Acumen pharmaceuticals announces proposed public offering of common stock

Charlottesville, va. and carmel, ind., july 17, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. all of the shares to be sold in the offering are to be sold by acumen. in connection with the offering, acumen intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock. the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ABOS Ratings Summary
ABOS Quant Ranking